Key result
The methyl-substituted spiro-hydroquinone derivative SD3A inhibited mitochondrial function and selectively reduced collagen-mediated platelet activation and thrombus formation in vitro.
Why the study?
Treatment resistance and recurrence of thrombotic events are common with antiplatelet therapy, underscoring the need to identify new antiplatelet molecules that inhibit aggregation without increasing bleeding risk.
Do spiro-hydroquinone derivatives, specifically SD3A, inhibit platelet activation in vitro?
Do spiro-hydroquinone derivatives, specifically SD3A, inhibit platelet activation in vitro?
The spiro-hydroquinone derivative SD3A demonstrates promising in vitro antiplatelet activity by selectively inhibiting collagen-mediated activation via mitochondrial function blockade with low cytotoxicity.
High Resolution Image Download MS PowerPoint Slide The primary goal of antiplatelet therapy is to inhibit platelet aggregation without increasing the risk of bleeding. Treatment resistance and recurrence of thrombotic events are common, underscoring the need to identify new molecules with antiplatelet activity. In this research, we synthesized and characterized spiro-hydroquinone derivatives substituted with various aliphatic chain lengths (1–9 carbons) and evaluated the effect of these modifications on platelet activation. The structure–activity relationship study revealed that increasing the aliphatic chain length did not enhance antiplatelet activity; instead, it increased cytotoxicity and negatively affected solubility. Notably, the shortest molecule, SD3A, inhibits mitochondrial function and acts selectively on collagen-mediated activation, resulting in reduced thrombus formation without affecting coagulation, thereby representing a low risk of bleeding in vitro . These results identify ortho -carbonylhydroquinone spiro derivatives, specifically SD3A, as a promising antiplatelet molecule, demonstrating an optimal combination of low cytotoxicity and pathway-selective activity against collagen.
No takes yet. Share an insight, caveat, or question.
Morales-Malvarez et al. (2025) studied Thrombosis. Spiro-hydroquinone derivatives (SD3A) was evaluated on Platelet activation and thrombus formation. The methyl-substituted spiro-hydroquinone derivative SD3A inhibited mitochondrial function and selectively reduced collagen-mediated platelet activation and thrombus formation in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: